07:00 , Apr 15, 2013 |  BioCentury  |  Strategy

IP armamentarium

With the most stocked clinical pipeline among its RNAi peers, Alnylam Pharmaceuticals Inc. has made the leap from platform to products, building on an IP position that has enabled revenue-generating deals that footed the bill...
07:00 , Jul 16, 2007 |  BioCentury  |  Strategy

RNAi(ndependence)

Last week's deal between RNAi company Alnylam Pharmaceuticals Inc. and Roche will provide a big bolus of non-dilutive financing that ALNY will put to two uses: moving its pipeline through the clinic and working on...
08:00 , Feb 12, 2007 |  BC Week In Review  |  Clinical News

RTP-801i: Phase I started

Quark began a Phase I trial of RTP-801i to treat wet age-related macular degeneration (AMD). The trial is being funded by PFE which licensed RTP-801i from Quark in 2006 (see BioCentury, Oct. 2, 2006). The...
07:00 , Oct 2, 2006 |  BC Week In Review  |  Company News

Quark Biotech Inc., Alnylam, Pfizer, SR Pharma deal

PFE acquired exclusive worldwide rights to the gene RTP-801 from Quark. PFE said the gene is involved in the development of blood vessels that accelerate the progression of age-related macular degeneration (AMD). PFE also gained...
07:00 , Oct 2, 2006 |  BioCentury  |  Finance

Ebb & Flow

ImClone (IMCL) investors shaved $1.30 off the stock last week as they digested news that FDA approved a competing colorectal cancer antibody - Vectibix panitumumab - from Amgen (AMGN). The main question now is whether...
07:00 , Oct 2, 2006 |  BioCentury  |  Tools & Techniques

Restocking in AMD

With sales of its Macugen pegaptanib on the decline due to competition in the wet age-related macular degeneration market, Pfizer Inc. diversified its approach to the disease last week by licensing rights to a preclinical...
07:00 , Jun 19, 2006 |  BC Week In Review  |  Company News

BioSpring, Genzyme, SR Pharma, OctoPlus B.V. deal

SPA's Atugen AG subsidiary partnered with GENZ, BioSpring and OctoPlus to manufacture Atugen's Atu027 siRNA therapeutic for cancer. GENZ will manufacture the product's lipid delivery system, BioSpring will produce the siRNA molecules, and OctoPlus is...
07:00 , Apr 3, 2006 |  BioCentury  |  Finance

Ebb & Flow

Hunter-Fleming set off to a series B financing to support its neurology efforts, and now the U.K. company finds itself with much more, including a stake in a new company and a foothold in the...
08:00 , Jan 23, 2006 |  BioCentury  |  Finance

In and out at Novartis Venture

In and out at Novartis Venture In and out at Novartis Venture Novartis Venture Fund last week released its report card for 2005. The firm saw its portfolio shrink to 62 private companies (61 assuming...
07:00 , Aug 1, 2005 |  BioCentury  |  Finance

Ebb & Flow

As anyone who has ever built a valuation model knows, it is always possible to come up with a higher or lower price for a company simply by tweaking a few numbers. But what matters...